智翔金泰(688443.SH)：GR1802注射液青少年季节性过敏性鼻炎适应症获得药物临床试验批准通知书

Core Viewpoint - The company Zhixiang Jintai (688443.SH) has received approval from the National Medical Products Administration for the clinical trial of its product GR1802 injection, aimed at treating seasonal allergic rhinitis in adolescents [1] Group 1: Product Development - GR1802 injection is a recombinant fully human anti-IL-4Rα monoclonal antibody developed independently by the company [1] - The target of GR1802 injection is IL-4Rα, which specifically binds to the cell surface human IL-4Rα [1] - The mechanism of action involves blocking the binding of IL-4 and IL-13 to IL-4Rα, inhibiting downstream STAT6 phosphorylation, and suppressing CD23 upregulation, thereby reducing Th2-type inflammatory responses mediated by IL-4 or IL-13 [1]